Larimar Therapeutics Inc (LRMR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2024 | 09-2024 | 06-2024 | 03-2024 | 12-2023 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -80,604 | -51,780 | -36,281 | -14,654 | -36,949 |
| Depreciation Amortization | -4,938 | -3,833 | -2,194 | -503 | -1,532 |
| Accounts payable and accrued liabilities | 1,141 | 403 | 1,626 | 290 | -403 |
| Other Working Capital | 6,175 | 414 | 9,733 | 2,661 | -2,511 |
| Other Operating Activity | 7,466 | 5,851 | 2,717 | 1,795 | 7,936 |
| Operating Cash Flow | $-70,760 | $-48,945 | $-24,399 | $-10,411 | $-33,459 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | -84,872 | -104,248 | -131,582 | -68,364 | 33,517 |
| PPE Investments | -515 | -336 | -274 | N/A | -164 |
| Investing Cash Flow | $-85,387 | $-104,584 | $-131,856 | $-68,364 | $33,353 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 161,883 | 161,847 | 161,817 | 162,151 | 30 |
| Financing Cash Flow | $161,883 | $161,847 | $161,817 | $162,151 | $30 |
| Beginning Cash Position | 28,088 | 28,088 | 28,088 | 28,088 | 28,164 |
| End Cash Position | 33,824 | 36,406 | 33,650 | 111,464 | 28,088 |
| Net Cash Flow | $5,736 | $8,318 | $5,562 | $83,376 | $-76 |
| Free Cash Flow | |||||
| Operating Cash Flow | -70,760 | -48,945 | -24,399 | -10,411 | -33,459 |
| Capital Expenditure | -515 | -336 | -274 | N/A | -164 |
| Free Cash Flow | -71,275 | -49,281 | -24,673 | -10,411 | -33,623 |